Pierian and P4 Diagnostix Collaborate to Help Physician-Owned Laboratories
Pierian®, a global leader in advanced clinical genomics technology and services, is pleased to announce an exciting partnership with P4 Diagnostix®, a leading-edge network of nationally recognized laboratories. Now physician-owned laboratories (POLs) that specialize in urology, gastroenterology, or women’s health, can add next-generation sequencing (NGS) testing for hereditary cancer to their routine diagnostic practice.
Lowering the Barrier for In-House NGS Testing for POLs
Physician groups are eager to expand their in-house testing modalities to include advanced molecular testing. However, challenges such as clinical validation of NGS assays, technical assessments, overhead costs for additional headcount, and navigating the dynamic insurance reimbursement environment can pose significant challenges to deploying NGS in clinical practice.
Read the full press release here.
Are you going to LUGPA?
Visit Pierian and P4 Diagnostix at booth #107 from Nov. 10-12 at the Large Urology Group Practice Association (LUGPA) Annual Conference in Chicago, IL.
Lissa Nakhwa: [email protected]